Barbados vs United Kingdom: Statin use vs. average non-HDL cholesterol levels
Barbados
3.3
in 2018
United Kingdom
3.3
in 2018
Barbados rank
95th
United Kingdom rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Barbados
- United Kingdom
How they compare
Barbados currently reports 3.3 against 3.3 in United Kingdom, a difference of 0.
Across all 39 years both countries report, United Kingdom has been ahead every year.
Barbados ranks 95th and United Kingdom ranks 95th of 191 countries.
United Kingdom has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Barbados | United Kingdom | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.2 | 4.48 | 1.28 | United Kingdom |
| 1990s | 3.16 | 4.25 | 1.09 | United Kingdom |
| 2000s | 3.18 | 3.89 | 0.71 | United Kingdom |
| 2010s | 3.26 | 3.48 | 0.2222 | United Kingdom |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Barbados or United Kingdom?
- Barbados, at 3.3 against 3.3 in United Kingdom as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Barbados and United Kingdom?
- 0, with Barbados ahead.
- How many years of comparable data are there for Barbados and United Kingdom?
- 39 years are reported by both, from 1980 to 2018.
- How do Barbados and United Kingdom rank globally for statin use vs. average non-hdl cholesterol levels?
- Barbados ranks 95th and United Kingdom ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.